300. IgG4-related disease Clinical trials / Disease details
Clinical trials : 36 / Drugs : 49 - (DrugBank : 22) / Drug target genes : 16 - Drug target pathways : 98
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04602598 (ClinicalTrials.gov) | January 15, 2022 | 20/10/2020 | Zanubrutinib in Patients With IgG4-Related Disease | A Phase II, Single-Site, Open-Label Study of Zanubrutinib in Patients With IgG4-Related Disease | IgG4 Related Disease | Drug: Zanubrutinib 80 MG | Matthew C. Baker | Stanford University | Not yet recruiting | 18 Years | 85 Years | All | 10 | Phase 2 | United States |